Literature DB >> 8553555

Identification of immunodominant regions and linear B cell epitopes of the gE envelope protein of varicella-zoster virus.

W J Fowler1, M Garcia-Valcarcel, M S Hill-Perkins, G Murphy, D R Harper, D J Jeffries, N R Burns, S E Adams, A J Kingsman, G T Layton.   

Abstract

The envelope proteins of varicella-zoster virus (VZV) are highly immunogenic and one of the most abundant is glycoprotein E (gE). However, its immunodominant regions and epitopes have not been identified. In this study, using human sera from individuals with recent varicella or zoster infections, we have localized antigenic sequences of gE using recombinant hybrid Ty-virus-like particles (VLPs) carrying overlapping fragments of the gE protein. gE(1-134)-VLPs (particles carrying amino acids 1-134 of gE) and, to a lesser extent, gE(101-161)-VLPs were found to be the most antigenic when tested by Western blotting and ELISA. Other fragments of gE (spanning residues 161-623) showed weak or no antigenicity. Pepscan analysis of human sera on overlapping synthetic peptides representing residues 1-135 of gE revealed that the most antigenic region was between residues 50 and 135. Three immunodominant sequences (residues 86-105, 116-135, and, to a lesser extent, 56-75) were detected using sera from both varicella and zoster patients. All sera from varicella, but not zoster, patients reacted strongly with an epitope in peptide 66-85. Other epitopes were recognized weakly by some varicella or zoster sera. More sera need to be tested to assess the potential disease specificity of these epitopes. The neutralizing monoclonal antibody (MAb) IF-B9 reacted with residues 71-90; however, another neutralizing MAb, SG1A, which bound to both gE(1-134)-VLPs and gE(101-161)-VLPs did not bind to any peptide. The identification of immunodominant sequences of gE will help toward the development of a subunit VZV vaccine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8553555     DOI: 10.1006/viro.1995.0064

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  5 in total

1.  Varicella-zoster virus transcriptome in latently infected human ganglia.

Authors:  Maria A Nagel; Alexander Choe; Igor Traktinskiy; Robert Cordery-Cotter; Don Gilden; Randall J Cohrs
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

2.  Global Mapping of O-Glycosylation of Varicella Zoster Virus, Human Cytomegalovirus, and Epstein-Barr Virus.

Authors:  Ieva Bagdonaite; Rickard Nordén; Hiren J Joshi; Sarah L King; Sergey Y Vakhrushev; Sigvard Olofsson; Hans H Wandall
Journal:  J Biol Chem       Date:  2016-04-15       Impact factor: 5.157

3.  Serological Evaluation of Immunity to the Varicella-Zoster Virus Based on a Novel Competitive Enzyme-Linked Immunosorbent Assay.

Authors:  Jian Liu; Xiangzhong Ye; Jizong Jia; Rui Zhu; Lina Wang; Chunye Chen; Lianwei Yang; Yongmei Wang; Wei Wang; Jianghui Ye; Yimin Li; Hua Zhu; Qinjian Zhao; Tong Cheng; Ningshao Xia
Journal:  Sci Rep       Date:  2016-02-08       Impact factor: 4.379

4.  Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.

Authors:  Lichen Jing; Kerry J Laing; Lichun Dong; Ronnie M Russell; Russell S Barlow; Juergen G Haas; Meena S Ramchandani; Christine Johnston; Soren Buus; Alec J Redwood; Katie D White; Simon A Mallal; Elizabeth J Phillips; Christine M Posavad; Anna Wald; David M Koelle
Journal:  J Immunol       Date:  2016-01-25       Impact factor: 5.422

5.  Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine.

Authors:  Michel Fochesato; Najoua Dendouga; Mathieu Boxus
Journal:  Hum Vaccin Immunother       Date:  2016-03-02       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.